Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Marvel Biosciences’ Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.